DepoMed, Inc. (DEPO)
A specialty pharmaceutical company focused on the development and commercialization of differentiated products that address growing markets and are based on proprietary oral drug delivery technologies.
Recs
strong drug development chain
Recs
Drugs er bad, mmm kay!!
Recs
Mmm...pharmaceuticals...
Recs
Recs
Phase III trials are currently under way on a drug for hot flashes. Standard treatment for hot flashes used to be hormone replacement therapy, which carries an increased risk of heart attack, stroke, and breast cancer. See http://www.medicinenet.com/alternative_treatments_for_hot_flashes/page2.htm
Current alternative treatments include SSRIs - selective seratonin reuptake inhibitors (primary indication in treating depression and anxiety), Clonodine (blood pressure medication, with annoying side effects such as dry mouth and constipation), various forms of progesterone (not all safe for long term use), and Depomed's Gabapentin (primary indication in treatment of seizures, well-tolerated by most women, main side effect being drowsiness). See http://www.medicinenet.com/alternative_treatments_for_hot_flashes/page3.htm
When studies were published early this decade linking HRT with serious health issues, the amount of money spent on HRT dropped significantly (actual numbers are in Depomed's 2008 Annual Report). Depomed stands to capture a significant portion of that market if Gabapentin proves effective, which is anticipated.
Recs
I have been involved with this stock for awhile now and it has continued to increase in value slowly. the pace over the last week has quickened and I look for it to continue. Sales continue to rise and new products are being developed and licensed. I am begining to look at this company as a buy out caindidate for one of the big pharco's
Recs
< 10% Price gain in last Qtr. 6month and Year. <10 5 Year Growth Rate. <10 Net Profit Margin. Last price above 50 and 200 day moving average. Debt to QEquity < 1. P/E <10
Recs
magicformulainvesting.com screen at $153M market cap, top 25 companies on June 26, 2008
Recs
It's Depo-tastic!
Recs
Appears to be headed in the right direction. A portion of 2007 gains came from terminating promotion agreement with King Pharmaceuticals. However, sales and income numbers are on the rise. I'm taking a risk and keeping my fingers crossed
Recs
EXP POS EARN
Recs
good fundamentals.
Recs
Unknowen till FDA approval thoght it received a lot of $ due to
Recs
Wow just went down 60%. haha
see if they bounce back?
Recs
Just a matter of time before it blows up..
Recs
negative earnings, negative cash flow, can't understand for the life of me why this is a ***** stock. now watch me gets burned as it adds 160% in the next three weeks :-)
Recs
I found this stock in December of 2006 when it was at $2.92 a share. Their product is unique and marketable and while the ride up (and down and up agian) can be frustrating I have it down as $6 per share before Christmas.
Recs
volatile 10~30%
Recs
A small pharma with good tech,pipeline, and patents.
Recs
Great choice to invest. New drug will become pop.

RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 22 1 2 Next »